RE:RE:RE:What could move share price upward?That is true Hank but as I posted earlier not necessarily bad news as it may let them refer to proven positive consequences of the second treatment in the 3-month CR ann.
Hindsight`s a great thing and the opportunity cost of holding Theralase must have been huge for me over the past 5 yrs +.The worst was the silence between P4 and P5 in 1B but this was the very time that the treatment was optimised - that is the quality of our Scientists.
The Clinic is all that matters.The Newsletter was a primer for yet more capitulation selling and a nineteenth nervous shakedown for weak hands - it will let them yo-yo the stock for a while longer but for what really matters it will all come down to the Clinic.
Only you can judge whether you`ve got better things to do with you money until an FDA ann or initial efficacy data and whether you can be sure to be in the stock in the amount that you want when that time comes.